Adverum Biotechnologies Inc. (NASDAQ:ADVM) saw an upside of 1.95% to $2.09 after adding $0.04 on Tuesday. The 5-day average trading volume is 2,266,053 shares of the company’s common stock. It has gained $2.16 in the past week. An average of 3,853,223 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,317,769.
ADVM’s 1-month performance is -8.48% or -$0.16 on its low of $2.00 reached on 10/06/21. The company’s shares have touched a 52-week low of $2.00 and high of $14.79, with the stock’s rally to the 52-week high happening on 01/20/21. YTD, ADVM has lost -81.09% or -$8.76. However, the current price is down -85.87%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Sep 30, 12 days have gone by since the last insider trading activity for Adverum Biotechnologies Inc. (ADVM). Clark Julie (Chief Medical Officer) most recently sold 4,766 shares at $2.17 per share on Sep 30. This transaction cost the insider $10,342. President and CFO, PATTERSON LEONE D, sold 12,533 shares at a price of $14.10 on Feb 09.
Adverum Biotechnologies Inc. (ADVM) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.25 for the sector.ADVM stock has a beta of 1.10. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 26.82 while the price-to-book (PB) in the most recent quarter is 0.53.
Adverum Biotechnologies Inc.’s quick ratio for the period ended June 29 was 18.80, with the current ratio over the same period at 18.80 meaning that ADVM stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00.
For the quarterly period ending June 29 this year, Adverum Biotechnologies Inc.’s cash and short-term investments amounted to $316.54 million against total debt of $129.55 million. Analysts expected ADVM to announce -$0.39 per share in earnings in its latest quarter, but it posted -$0.45, representing a -15.40% surprise. EBITDA for the quarter stood at more than -$41.3 million. ADVM stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 147.0 million, with total debt at $129.55 million. Shareholders hold equity totaling $98.13 million
Let’s look briefly at Adverum Biotechnologies Inc. (ADVM) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 40.98% to suggest the stock is trending Neutral, with historical volatility in this time period at 80.43%.
The stock’s 5-day moving average is $2.06, reflecting a -3.70% or -$0.08 change from its current price. ADVM is currently trading -4.15% above its 20-day SMA, -40.91% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -12.61% and -83.06% respectively.
Stochastic %K and %D was 12.18% and 11.32% and the average true range (ATR) pointed at 0.14. The RSI (14) points at 41.64%, while the 14-day stochastic is at 15.38% with the period’s ATR at 0.14. The stock’s 9-day MACD Oscillator is pointing at -0.07 and -0.12 on the 14-day charts.
In the most recent analyst report for Adverum Biotechnologies Inc. (NASDAQ: ADVM), Cantor Fitzgerald downgraded it to a Neutral rating. They previously had an Overweight rating on the stock. Analysts offering their rating for ADVM stock have a consensus rating for the stock as Hold. Currently, 0 brokerage advisors rate ADVM as a “sell,”, while 7 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is ADVM’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $2.00 and a high of $6.00, with their median price target at $3.00. Looking at these predictions, the average price target given by analysts is for Adverum Biotechnologies Inc. (ADVM) stock is $3.57.